The recently released State Council Document No. 13 has for the first time put forward a comprehensive reform plan for China's pharmaceutical market, which would lead to a great impact--even a reshuffle--for the industry players. The Document No. 13 provisions have a full coverage of the entire chain of pharmaceutical industry, including drug registration, quality assurance, R&D, production, distribution and use.
Prior to the release of the document, pilot reform programs have been rolled out in different provinces nationwide. The pilot program in Sanming City, Fujian Province, has attracted much attention and has been deemed as a replicable model since its very beginning. The influence of the reform for government administration, pharmaceutical industry, healthcare system and hospitals are far-reaching.
In the upcoming Pharma Working Group meeting, we are delighted to invite Ms. Jenny Yao from KPMG and Ms. Helen Chen from L.E.K. to share their insights on the healthcare reform, industry development, and impact of Document No. 13 and Sanming Model.
Tentative Agenda
09:45-10:00 Registration
10:00-10:05 Welcome remarks by Pharma Working Group Chair
10:05-10:35 Pharma industry development from policy angle (Helen)
10:35-11:05 Sanming Model and its impacts (Jenny)
11:05-11:45 Q&A and discussion